Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirelizumab + axitinib ± SBRT in oligometastatic advanced renal cell carcinoma
ChiCTR2200067043Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tislelizumab and axitinib in renal cell carcinoma (RCC) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Objective response rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
tislelizumabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2200067043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067043.